Introduction
Brugada syndrome (BS) is an inherited disease characterized by coved-type ST-segment elevation in the right precordial leads and increased risk of sudden cardiac death (SCD) in the absence of structural heart disease. 1 Since the first description of the syndrome, more than 20 years ago, the search of predictors to identify those patients at risk of arrhythmic events has been ongoing. As arrhythmic risk persists life long, studies with a very long follow-up are of upmost importance. Nevertheless, mean follow-up in the available literature is usually shorter than 3 years. 2, 3 Many risk factors have been described, some consistently reported, such as type I electrocardiogram (ECG) pattern or symptomatic patients, 2, 4 whilst others remain under deep controversy, specifically inducible ventricular arrhythmias (VA) during electrophysiological study (EPS). 3, 5, 6 Furthermore, implantable cardioverter risk. 4, 7 Implantable cardioverter defibrillator implantation is recommended in those BS patients that have suffered an aborted SCD or have a spontaneous sustained ventricular tachycardia (VT), when presenting syncope and spontaneous type I ECG and it might be considered when VA are induced during EPS. 8 As patients are otherwise healthy individuals at their forties, risk of device related complications and inappropriate shocks are relevant. 9 Due to all these considerations, decision making in BS syndrome is still challenging. The purpose of this study was to analyse our single-centre 20 years' experience in BS patients, focusing on the search of arrhythmic events predictors. We sought to construct a comprehensive and simple risk score to help in the management of patients.
Methods

Study population
Since 1992, all consecutive patients diagnosed with BS in the Universitair Ziekenhuis Brussel have been included in a registry and followed in a prospective fashion. Patients were included until end 2013. The ethics committee approved the study protocol. Inclusion criteria were: spontaneous or drug-induced Brugada type I ECG and follow-up longer than 1 year. Patients followed at out centre were used for the analysis and creation of a score and those patients not followed in our centre were used as an external validation cohort. Medical history, physical examination and baseline ECG were obtained and underlying structural cardiac abnormalities were excluded. Electrocardiograms were classified as Brugada type I, type II, or normal. An ECG was considered diagnostic if a coved type ST elevation > _2 mm was documented in > _1 lead from V1 to V3 in the presence or absence of a sodium-channel blocker. Electrocardiograms were performed with the leads positioned at the sternal margin of the third and fourth intercostal space. Two independent electrophysiologists analysed all ECGs; in case of disagreement a third was consulted. A 'proband' was defined as the first Brugada patient diagnosed in a family based on a type 1 Brugada ECG pattern. Patients presenting an aborted SCD or a syncope were considered as symptomatic. Syncope was considered if suspected to have arrhythmic origin. Syncope workup included transthoracic echocardiography and Holter monitoring. It was considered arrhythmic in the absence of prodromes and triggering circumstances and in the presence of brief loss of consciousness or severe trauma. Specific attention was paid to exclude vasovagal syncope. Diagnosis of sinus node dysfunction (SND) was based on the correlation of symptoms with the presence of documented arrhythmias such as sinus bradycardia, sinus arrest, paroxysmal supraventricular tachycardia alternating with periods of bradycardia, or even asystole. Chronotropic incompetence, characterized by an impaired heart rate response to exercise, was considered as an additional manifestation of SND and was defined as failure to achieve 85% of the age-predicted maximum heart rate. Conventional 24-or 48-h Holter monitoring was performed in any case of suspected SND. Moreover, electrophysiological evaluation of SND was performed in all patients who underwent an EPS. Electrophysiological evaluation of SND included measurement of sinus node recovery time (SNRT) (considered abnormal if more than 1500 ms), corrected SNRT (more than 550 ms), SNRT/sinus cycle length 100% (more than 160%), and sinoatrial conduction time (more than 125 ms). Supraventricular arrhythmia as a cause of syncope was also tested during EPS if appropriate.
Drug challenge
Ajmaline (1 mg/kg) was administered intravenously over a 5 min period to unmask the diagnostic pattern in case of non-diagnostic baseline ECG.
Flecainide (2 mg/kg) or procainamide (10 mg/kg) were administered over 10 min as an alternative. The test was considered positive if type I ECG was documented in > _1 right precordial leads. The drug infusion was discontinued if QRS prolongation exceeded 30%, frequent premature ventricular beats or type I Brugada ECG occurred or development of highdegree artrio-ventricular block.
Electrophysiological study
Electrophysiological study protocol used a single site of stimulation (right ventricular apex), three basic pacing cycles (600, 500, and 430 ms), and introduction of up to three ventricular premature beats down to a minimum of 200 ms. It was considered inducible if a ventricular fibrillation (VF) or ventricular tachycardia (VT) lasting at least 30 s was induced.
Implantable cardioverter defibrillator implantation
Beginning from 2005, the indication to ICD therapy was determined using the recommendations of the second Brugada consensus conference. 10 Implantable cardioverter defibrillator programming at the time of implantation changed over the time. Ventricular fibrillation detection rate was increased from 180 to more than 200 b.p.m. for primary prevention implants, 11 long-detection intervals were adopted in order to avoid unnecessary therapies. 12 Conversely, in patients receiving ICD therapy for 
Follow-up
Clinical follow-up of patients was performed at least every 6 months in case of device therapy patients and every 2 years otherwise. All patients were contacted via telephone and post mail in 2007 and 2012. We keep a specific database managed by a dedicated research nurse (G.P.). Arrhythmic events refer to SCD and appropriate ICD shocks. Deaths secondary to other causes were censored. Implantable cardioverter defibrillator implantation not due to a resuscitated SCD was not considered as an event. All patients with an event within the first year had a follow-up longer than 1 year. All available electrograms of shocks were analysed by at least two investigators independently. Electrical storm was defined by three or more sustained VAs or ICD appropriate shocks within 24 h.
Statistical analysis
All data and analysis presented in this study, were performed in the training cohort. Hazard ratios were calculated using Cox proportional hazards models. Variables selected for the analysis were those that had previously demonstrated a predictive value in the BS literature and those that we thought that had biological plausibility to predict events. A predictive model containing all variables related with events in the univariable analysis was constructed. Predictive performance was evaluated by means of Heagarty's C. 13 Among the reduced models, the simplest one with a predictive performance loss of less than 10% was selected as the final model. The selected model was validated in the external cohort by means of Heagarty's C. A P-value less than 0.05 was considered statistically significant. Statistical analyses were conducted using the SPSS software (v22, Chicago, IL, USA).
. 
Results
Study population
Four hundred consecutive patients with BS fulfilled the inclusion criteria (mean age 41.1 ± 17.8 years, range: 6 months to 80 years). Table  1 shows baseline characteristics and evolution along the years. Seventy-eight (19.5%) patients presented a spontaneous type I ECG, the remaining 322 (80.5%) were diagnosed by means of drug challenge (303 (91.1%) ajmaline, 6 (1.9%) procainamide and 13 (4.0%) flecainide).
Aborted SCD was the clinical presentation in 20 (5.0%) patients, syncope in 111 (27.8%) and the remaining 269 (67.3%) were asymptomatic. Thirty-four (8.5%) patients had history of atrial fibrillation (AF) and 8 (2.0%) presented SND. Table 2 shows baseline characteristics according to symptoms at presentation.
Familial antecedents of SCD were present in 184 (46.0%), in 31 (7.8%) in a first-degree relative younger than 35 years. Electrophysiological study was performed in 365 (91.3%) patients, in 72 (19.7%) a sustained VA was induced. One hundred twenty-two (30.5%) were probands. A total of 215 genetic tests (53.8%) were obtained and 53 (25.5%) were positive for a SCN5A gene mutation.
Management
An ICD was implanted in 176 (44.0%) patients. It was placed in 95.0% (19) of patients presenting an aborted SCD, 89.2% (99) of those with syncope and in 21.6% (58) asymptomatic. Patients receiving an ICD were significantly older (43.5 ± 17.0 vs. 39.5 ± 18.1, P = 0.03), more frequently male (50.6% vs. 34.7%, P < 0.01) and more commonly presented a spontaneous type I pattern (64.1% vs. 39.1%, P < 0.01). Longer PR (179.9 ± 31.3 ms vs. 169.3 ± 32.9 ms, P = 0.01) and broader QRS (106.2 ± 19.0 ms vs. 20.5 ms, P < 0.01) was registered in ICD patients. Probands underwent more frequently ICD implantation (71.3% vs. 32.0%, P < 0.01).
Follow-up
After a mean follow-up of 80.7 ± 57.2 months (range 1.4-298.0), 34 (8.5%) arrhythmic events occurred, accounting for a rate of 1.4% year. Follow-up was available for all patients. Kaplan-Meier event free survival was 96.5% at 1 year, 91.4% at 5 years and 89.3% at 10 and 15 years. Events consisted in 4 (1%) SCD (one successfully reanimated) and 30 (7.5%) VA, appropriately treated by ICD therapies.
Four (1.0%) patients presented an electrical storm during followup. All initially presented as aborted SCD, 3 (75.0%) were men, 2 (50.0%) had a spontaneous type I ECG, mean age was 41.0± 10.3 years and 2 (50.0%) had already received an appropriate ICD therapy.
Twelve (3%) patients died during follow. Aetiology was SCD in three patients, ischaemic heart disease in one, septic shock after device revision in one and the remaining seven suffered a non-cardiac death.
Eight patients presented a supraventricular tachycardia during the follow-up: six atrioventricular nodal re-entry tachycardia, one flutter, and one focal atrial tachycardia. Thirty-four patients presented AF. In four of whom coexisted with SND. Eight patients received quinidine during follow-up.
Risk factors associated to events
Symptoms at presentation Patients initially presenting symptoms had a worse prognosis (HR 5.67, 95% confidence interval [CI] 2.6-12.7, P < 0.01) (Figure 1 4 , P < 0.01) and syncope of 3.7 (95% CI 1.6-8.6, P < 0.01). Arrhythmic event incidence rate was 11.1% year for patients presenting with aborted SCD, 2.2% year for syncope and 0.6% year for those asymptomatic.
Electrocardiogram pattern
Patients with spontaneous type I ECG were at a higher arrhythmic risk (HR 2.7, 95% CI 1.3-5.4, P < 0.01). Event incidence rate was 2.3% year for the spontaneous type I patients and 1.1% year for those drug-induced.
Gender
Male patients had worse prognosis (HR 2.7, 95% CI 1.2-6.2, P = 0.02). Incidence rate in women was 0.7% year vs. 2.0% year in men.
Family history of SCD Family history of SCD lacked a statistical relationship with events (HR 0.6, 95% CI 0.3-1.3, P = 0.20). Conversely, when considering SCD in 1st-degree relatives younger than 35 years, it resulted significant, with a HR of 2.9 (95% CI 1.2-7.0, P = 0.02) (Figure 1 ). Patients with early SCD in first-degree relatives had an event incidence rate of 3.1% year as compared with 1.3% year if it was not present.
Sinus node dysfunction
Those patients presenting concomitant SND had a significantly worse prognosis (HR 5.0, 95% CI 1.5-16.3, P < 0.01) (Figure 1 ). Incidence rate was 4.3% year in patients with SND and 1.3% year in those without. Table  3 shows clinical characteristics and events in patients presenting SND.
Electrophysiological study Inducible VA during EPS conferred a significant higher risk for events (HR 4.7, 95% CI 2.2-10.2, P < 0.01) (Figure 1 
Other risk factors
Proband status and QRS duration (per ms) showed a significant relation with events (HR 2.1, 95% CI 1.0-4.2, P = 0.04 and HR 1.03, 95% CI 1.01-1.04, P < 0.01, respectively). History of AF presented a nonsignificant borderline association (HR 2.3, 95% CI 0.9-5.6, P = 0.07).
Risk score model
A model with all variables that showed statistical relationship with events was created. The variables included were gender, presentation as syncope, as aborted SCD, SND, proband status, early familial antecedents of SCD in first-degree relatives, spontaneous type I pattern, QRS duration and VA inducibility. This model had a high predictive performance: 0.90. Amongst the reduced models, the selected one included presentation as syncope, as aborted SCD, spontaneous type I pattern, SND, early familial antecedents of SCD in 1st-degree relatives and inducible VA. Predictive ability of this model was high: 0.82. When applied to asymptomatic patients, it was 0.81, for syncope patients: 0.63 and for patients presenting after and aborted SCD it was 0.71. If applied to asymptomatic or syncope patients it was 0.79.
A risk score for this model was constructed by rounding the regression coefficients. Performance of the score was the same as the model (0.82). Figure 2 shows the score and its performance. Examining the data, we found that patients with a score greater than 2 presented a significant higher event probability as compared with lower scores (P = 0.02). A score of two points conferred an event Table 4 shows clinical characteristics of patients according to the score and Table 5 the event free survival in each category.
External validation of the proposed score A cohort of 150 BS patients was assessed for external validation of the model. The validation cohort presents some differences as compared with the training cohort. Table 6 shows baseline clinical characteristics and event rates of both cohorts. Patients in the validating cohort were older with a mean age of 45.9 ± 13.2 years, male sex was more frequent (83.3%) and patients displayed more the spontaneous type I ECG pattern (52.7%). Symptoms at presentation and VA inducibility were distributed similarly. Consequently, the mean score punctuation was higher (1.89 ± 1.84 vs. 1.44 ± 1.79 points). Event incidence rate was also higher (1.9% per year vs 1.4% per year). The score performance in the validating cohort was 0.81.
Discussion
The most challenging issue in the management of BS patients is identifying those at risk of SCD. Some risk factors, such as symptoms or spontaneous type I pattern have been consistently associated to a worse prognosis, 2,4,7 whilst controversy still exists around others, as the role of EPS. 5 Furthermore, most studies in BS have a mean follow-up not longer than 3 years and, as arrhythmic risk persists lifelong, studies with very long follow-up are needed. We present a big cohort of BS patients followed for a mean of 80 months. This constitutes the longest follow-up published heretofore. Amongst the main BS registries, only FINGER involved more patients but our follow-up is almost three times longer. 2 The aim of our study was to offer a simple tool to stablish the arrhythmic risk in BS. We confirm the value of some widely accepted risk factors such as spontaneous type I pattern and symptomatic presentation. We present further evidence supporting others, as inducible VAs during EPS, sex or SND. A relation between arrhythmic events and familial history of early SCD was found.
14 A risk score model has been constructed provide a comprehensive approach that might help in the management of BS patients.
Clinical profile
Recent evidence shows a shift in the clinical profile of BS patients. 15 Higher risk patients were described in the early years after the description of the syndrome. In our study patients had a mean age of 41 years. Male sex was predominant but more than 40% were females, a fact already highlighted in a recent publication. 16 This contrasts with the main BS registries, 2, 3 where women constituted only 20-30% of the population. We believe that this might be due to meticulous familial screening and proactive search in patients with suspicion of BS. Twenty percent of patients presented spontaneous type I ECG and most patients were asymptomatic. Interestingly 46% of patients had a history of SCD in their family and 8% in a 1st-degree relative younger than 35 years. In the FINGER, registry age of diagnosis and symptomatic status at presentation are similar but around half of the patients presented a spontaneous type I pattern. 2 The PRELUDE registry presented a similar profile. 3 Inducible VA during EPS were found in 20% of our patients. Contrast with the main BS registries is notorious, as inducibility rates are much higher in the former studies. This could be explained by differences in the stimulation protocol, less aggressive in our cohort. Therefore, clinical profile of the patients present in this study is more favourable than those in the main BS registries, furthermore it has evolved over time. This could be of importance as it might represent better the profile of BS patients diagnosed nowadays.
Long term follow-up and risk factors for arrhythmic events
Arrhythmic event rate is crucial to provide robust management recommendations. Event rate in our study is 1.4% year, similar to FINGER and PRELUDE (1.6% and 1.5%, respectively).
2,3 Amongst risk factors, familial history of SCD, EPS inducibility and SND merit special consideration. Relation between familial history of SCD and prognosis has not been consistently reported. Our group published a specific study addressing this issue, finding that multiple SCD in 1st-degree relatives younger than 35-years-old were predictive of future events.
14 In the present study, almost 50% of patients have a family history of SCD but in only 10% in a young first-degree relative. The genetic background of the syndrome makes reasonable to expect a high incidence of SCD in those families with a more severe form of the disease. Nevertheless, all major registries have failed in finding this association. 2, 3 In the present study, early familial antecedents of SCD confers a HR of 2.9 (adjusted of 4.0), a similar magnitude as spontaneous type I. Another interesting finding is that SND is related to a more severe form of the disease. Sodium channelopathies have already been associated to SND. 17 Patients presenting SND tend to be young, specific- 
Risk model
Risk stratification in BS is complex and many factors should be taken in consideration. Implantable cardioverter defibrillator implantation entails potential long-term complications, therefore risks and benefits should be carefully evaluated. We sought to develop a risk model with enough predictive performance to help in the management of patients. Based on a maximum model we simplified it without a substantial power loss. The selected model has six items including novel markers such as SND and early family history of SCD. This model had a good predictive performance in the training cohort To add further support of the value of our score, it was tested in a validating cohort of 150 BS patients. Of note, the validation cohort presented some differences as compared with the training one. Briefly, patients in the validating cohort had a higher arrhythmic risk profile: spontaneous type I pattern was more frequent, they were more frequently male and probands. As a reflect of this, arrhythmic events were more frequent. However, the score performed well in the validating cohort, with a similar performance.
Establishing a threshold that classifies patients as high risk is difficult and open to a variety of opinions. An estimated 5-year event risk of 6% seems reasonable as it is used to recommend ICD implantation in patients with hypertrophic cardiomyopathy. 8 This corresponds to a score of two points in our model. Nevertheless, the decision for an aggressive management should be based in objective data but should be done individually, taking into consideration patients' preferences and clinicians' experience.
Limitations
Patients with BS present a lifelong risk of arrhythmias and even longer follow-up is advisable. The overall number of events might limit the search of predictors. This limited number of events might also over fit the score model. Competing risks might be of relevance;
nevertheless, their effect is probably small as the population is composed by healthy individuals. Implantable cardioverter defibrillator shocks as a surrogate of SCD in BS population overestimates arrhythmic events, 22 however, is a common endpoint in BS registries. 2, 3, 6 Validation of the score system in another large cohort would add more support to its utility and confirm the value of the selected risk factors.
Conclusions
The present study, with the longest follow-up published to date, demonstrates that BS patients have an overall event rate of 1.4% year. We add more clinical evidence to widely accepted risk factors, as presentation symptoms and ECG pattern. Inducible VA during EPS and other novel factors such as SND and early familial history of SCD predict events. The proposed risk model has a good predictive value and can help in the management of BS patients. 
